Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
IPO Year:
Exchange: NASDAQ
Website: rezolutebio.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/5/2024 | $12.00 | Outperform | Wedbush |
8/27/2024 | $11.00 | Buy | Guggenheim |
7/17/2024 | $13.00 | Buy | BTIG Research |
6/4/2024 | $14.00 | Buy | Craig Hallum |
4/9/2024 | $8.00 | Buy | Maxim Group |
8/2/2022 | $17.00 | Buy | Canaccord Genuity |
6/15/2022 | $9.00 | Overweight | Cantor Fitzgerald |
11/29/2021 | $30.00 → $17.00 | Buy | Canaccord Genuity |
11/15/2021 | $30.00 → $18.00 | Market Outperform | JMP Securities |
9/8/2021 | $21.00 | Buy | ROTH Capital |
Wedbush initiated coverage of Rezolute with a rating of Outperform and set a new price target of $12.00
Guggenheim initiated coverage of Rezolute with a rating of Buy and set a new price target of $11.00
BTIG Research initiated coverage of Rezolute with a rating of Buy and set a new price target of $13.00
Craig Hallum initiated coverage of Rezolute with a rating of Buy and set a new price target of $14.00
Maxim Group initiated coverage of Rezolute with a rating of Buy and set a new price target of $8.00
Canaccord Genuity resumed coverage of Rezolute with a rating of Buy and set a new price target of $17.00
Cantor Fitzgerald initiated coverage of Rezolute with a rating of Overweight and set a new price target of $9.00
Canaccord Genuity reiterated coverage of Rezolute with a rating of Buy and set a new price target of $17.00 from $30.00 previously
JMP Securities reiterated coverage of Rezolute with a rating of Market Outperform and set a new price target of $18.00 from $30.00 previously
ROTH Capital initiated coverage of Rezolute with a rating of Buy and set a new price target of $21.00